Anti-Human CD22 Recombinant Antibody (23C6) (CAT#: TAB-1718CL)

Figure 1 is a graph shows ADCC activity (as measured by % lysis) of anti-CD22 human antibodies 12C5, 19A3, 16F7 and 23C6 against Daudi cells.

Figure 2 is a graph shows ADCC activity (as measured by % lysis) of anti-CD22 human antibodies 12C5, 19A3, 16F7 and 23C6 against Raji cells.

Figure 3 is a bar graph shows the internalization of anti-CD22 human antibodies 12C5, 19A3, 16F7 and 23C6 into Raji cells.

Figure 4 is a bar graph shows the effect of immobilized anti-CD22 human antibodies 12C5, 19A3, 16F7 and 23C6 on BCR-stimulated Ramos cells, as measured by % cell death.

Figure 1 Anti-CD22 Antibody (TAB-1718CL) in Flow Cytometry

Flow cytometry analysis of Daudi cells with anti-CD22 antibody (Cat#TAB-1718CL, Blue line) or isotype control antibody (Yellow line). A Goat Anti-human IgG (FITC) was used as the secondary antibody.

Figure 2 Anti-CD22 Antibody (TAB-1718CL) in ELISA

ELISA analysis of TAB-1718CL was performed by coating with CD22 Protein, Human, Recombinant (His Tag).
The secondary antibody: HRP-Anti-Human IgG (H+L)

Figure 3 Anti-CD22 Antibody (TAB-1718CL) in WB

Western blot analysis of TAB-1718CL was performed with CD22 Protein, Human, Recombinant (His Tag).
TAB-1718CL incubation concentration: 2ng/μL.
The secondary antibody: HRP-Anti-Human IgG (H+L)
Lane 1: Reducing antigen (0.8μg)